Read as much as you want on, anywhere and anytime, for just 99¢.

Mass. Movers

Biogen Idec slips as MS drug’s sales slow

George A. Scangos is chief executive of Biogen Idec.

Jessica Rinaldi For The Globe

George A. Scangos is chief executive of Biogen Idec.

Continue reading below

Biogen Idec Inc. fell after demand for its multiple sclerosis drug Tecfidera showed signs of slowing. Prescriptions fell 6.7 percent in the week ended Aug. 2 to 3,377 from the previous week, IMS Health Inc. said. Tecfidera, said Gabelli & Co.’s Kevin Kedra, is “the newest oral MS product . . . It’s gotten off to a very strong launch, so any signs of them maybe slowing down would be a positive for competitors” like Teva Pharmaceutical, Bloomberg reported. Biogen Idec said it doesn’t comment on sales reports.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of